FCGR3A and neoplasm: The therapeutic potential of a CD16/CD19 BiKE and a CD16/CD19/CD22 TriKE has already been demonstrated in a preclinical study showing their ability to trigger NK cell functions in terms of cytokine and chemokine production, secretion of lytic granules and induction of tumor cell death (240).